Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 27, 2002

View Archived Issues

Antioxidants AEOL-10113 and AEOL-10150 have protective effects on isolated pancreatic islet cells

Oncogene BRAF is mutated in a high proportion of human melanomas

Novel GABA-A/BDZ modulators presented by Neurogen and Lilly at ACS meeting

Synthesis and SAR of new series of CRH1 antagonists reported in Boston

TACE inhibitors presented by Bristol-Myers Squibb at ACS

Compounds with potent and selective caspase-3 inhibitory activity disclosed by Merck Frosst

5-ASA-containing prodrugs for IBD presented at ACS

Aphton files for fast track designation for G17DT in gastric cancer

Gleevec granted priority review for first-line use in early CML

Sepracor and MedPointe to copromote Astelin

SGN-15 enters phase II in advanced ovarian cancer

Transition Therapeutics begins phase I trial of interferon enhancing therapy

Phase III Chronogesic trial placed on partial hold pending trial protocol amendments

BioMarin completes acquisition of Glyko Biomedical

Incara stops patient enrollment in deligoparin trial

Dual dopamine D4 and 5-HT2A receptor antagonists described by Lundbeck

Compounds with utility as 5-HT6 ligands claimed in patent

Boehringer Ingelheim claims telomerase-inhibiting carboxamides

Dr. Reddy's Research Foundation describes antibacterial compounds in patent

Kosan Biosciences describes compounds for gastrointestinal motility disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...